Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioInvent International AB ( (SE:BINV) ) has issued an update.
BioInvent International AB and Transgene have announced positive clinical results for their oncolytic virus BT-001, which shows promising antitumoral activity in combination with pembrolizumab in patients with advanced refractory tumors. The data presented at the ESMO 2025 Annual Meeting indicate that BT-001 is well tolerated and effective in shrinking tumors, supporting further development across a range of solid tumors. This development could enhance treatment options for cancer patients, particularly those with limited alternatives, by transforming cold tumors into immunologically active ones.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a biotech company focused on the discovery and development of novel antibodies for first-in-class cancer immunotherapy. The company collaborates with Transgene, which designs and develops virus-based immunotherapies for cancer treatment.
YTD Price Performance: -30.52%
Average Trading Volume: 85,607
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.76B
See more data about BINV stock on TipRanks’ Stock Analysis page.